Management, Science and Technology Corporation Unified (MSTC Unified)

Global Unified Business Carrier,Facilitation and Knowledge Centre

(A Mahesh Jackson strategic company powered by infinite absolute intellect, geniosity and generosity)


Centre for pharma and biotechnology                                                                                                                                                                         Advertisement

Indeed, dislike he's curing disease." It's a without any preparation remark that is tossed around when individuals consider their occupations excessively important. However, imagine a scenario where you truly could cure growth or different illnesses. On the other hand concoct new advances that could expand crop yields by 20 or 25 percent? That may be a justifiable reason motivation to consider your occupation important. Working with plant-and concoction based mixes, pharmaceutical organizations work their magic to make meds that cure a few ailments, oversee others, and shield us from contamination in any case. Huge Pharma incorporates a modest bunch of significant organizations that overwhelm the business. While a considerable lot of these organizations likewise create creature wellbeing items, animals sustain supplements, vitamins, and a large group of different merchandise, this profile will concentrate exclusively on their medication items used to treat human disease. Enormous Pharma is one of the world's most gainful ventures. Amid the most recent 30 years, the industry has burned through billions of dollars on examination and procured billions consequently. In 2006 alone, the pharmaceutical business presented 31 noteworthy medications and sold $643 billion in items around the world a 7 percent expansion more than 2005 deals, as per the medication statistical surveying firm IMS Health. U.S. deals beat the national normal with development of 8.3 percent (up from 5.4 percent development in 2005). Contingent upon their size and methodology, pharma organizations may lead broad examination in-house or they may try to permit promising medications from the scholarly world, other pharma firms, or biotechnology organizations. The last firms are for the most part littler than their Big Pharma rivals, and they utilize cell and biomolecular procedures to make solutions or analyze ailment.Biotechnology, a fresher territory, has then again been the sweetheart and the worst thing about financial specialists as of late. Basically, biotechnology, the connected learning of science, tries to copy or change the capacity of a living cell so it will work in a more unsurprising and controllable way. The biotechnology business utilizes progresses as a part of hereditary qualities examination to create items for human infections and conditions. A few biotech organizations likewise utilize hereditary innovation to different closures, similar to the control of products. Biotech open doors generally reflect those in the pharmaceutical business. The key distinction is that biotech firms are a great deal more centered around examination since they are as yet building up their underlying items. Biotech firms have a tendency to extend their advertising and deals strengths when-and if-a feasible item nears FDA endorsement. Furthermore, it's ended up regular for little organizations to look for unions with bigger organizations that as of now have the imperative framework set up for these capacities. This implies occupations for nonscientists are scarcer in biotech than in pharmaceuticals. Biotech and pharma have been performing exceedingly well in respect to different enterprises as of late. Keeping in mind there are issues sneaking in the shadows at a few organizations, by and large the future searches brilliant for these businesses. In spite of the fact that there is a lot of open debate (e.g., the good and moral inquiries encompassing genomics and the valuing and patent practices of Big Pharma), interest for medications is developing, powered by a maturing populace and blooming global markets. Despite whether you work for Big Pharma or little biotech, don't get excessively appended, making it impossible to the norm. Nowadays, the business environment can change overnight. One need just take a gander at late biotech stock instability for adequate confirmation of that. Also, as one insider says, "Even in Big Pharma, if there's a merger or a twist off, you can undoubtedly wind up without an occupation."

Evaluating -Insiders say this might be the greatest issue the business right now confronts. Who will pay the expense of medication improvement? As more medicines get to be accessible, will just the rich have entry to them?Physician recommended drug costs are rising every year, while back up plans are getting progressively more stringent about which prescriptions they'll repay their clients for. Energizing new medications can cost thousands or even a huge number of dollars per treatment. Giving value help to seniors has been an issue for quite a long while. Numerous support value controls to keep costs from soaring, a move the pharmaceutical business restricts.


A developing number of Big Pharma organizations are joining forces in medication advancement with development rich biotech firms, or purchasing the organizations out and out. In 2006, Big Pharma spent generally $17 billion for more than 250 biotech bargains, up from 150 in 2003, as per funding firm Burrill and Company. Besides, Big Pharma is progressively looking to biotech to help it discover potential treatments for fizzled clinical aggravates, a strategy called "repositioning." Pfizer's blockbuster Viagra is one case of finding another utilization for an apparent disappointment: The surely understood treatment for erectile brokenness started its gone through the pipeline as an exploratory heart solution. As of late, Pfizer, Roche, and Eli Lilly all marked manages the minor biotech firm Gene Logic to research their fizzled clinical competitors in the trust of making their R&D programs more gainful. Biotech organizations, particularly those managing agribusiness, are additionally adjusting to colleges to boost their exploration abilities. A few colleges, similar to the University of Rochester in New York, are creating focuses and hatcheries that will give youngster biotech organizations the assets they have to develop. THE RISE OF GENERICS,-At the point when a medication goes "off patent," other medication organizations are allowed to offer nonexclusive forms, synthetically indistinguishable duplicates that regularly cost significantly less than the trademarked rendition. The licenses on some of Big Pharma's most productive medications have lapsed in the previous couple of years. Illustrations incorporate Merck's Zocor, a cholesterol-bringing down medication; Pfizer's onetime blockbuster Zoloft, used to mitigate discouragement; and Bristol-Myers Squibb's cholesterol reducer Pravachol. These medications were focused in 2006 by Teva, the Israel-based nonexclusive pharmaceuticals producer.Yet, as non specific medication makers have turned out to be more forceful in their deals and showcasing endeavors, makers of marked pharmaceuticals have turned out to be more fiery in guarding their turf. Some Big Pharma organizations have procured bland medication makers, for example, Novartis' securing of Eon and Hexal. Those augmentations, and the company's obtaining of biotech firm Chiron, are a piece of Novartis' system of turning into a "one-stop shop" for its biggest medication clients: governments and oversaw care associations. Antibodies-Immunizations long held a low spot on the medication advancement command hierarchy as Big Pharma sought after items that customarily offered a superior degree of profitability. (Part of the explanation behind this is creating countries that need immunizations the frequently do not have the assets to pay for them.) The circumstance has changed, be that as it may, because of a recharged drive to deliver antibodies that will avoid or treat crushing sicknesses regular in the created world, for example, growth and Alzheimer's malady. A few specialists are anticipating that antibodies will in the long run supplant different solutions to wind up Big Pharma's greatest dealers.Today, there are around 450 immunizations being developed tending to such wellbeing dangers as hepatitis, HIV, and bosom growth. Drug firms are charging more for recently created antibodies than they could for more established ones, a circumstance that is impelling immunization R&D. Be that as it may, government/industry organizations are enhancing the immunization improvement picture, as well. The Group of Seven industrialized countries declared its dedication in mid 2007 to give $1.5 billion in a supposed "development market responsibility" to finance building up nations' buy of pneumococcal immunizations. The trust is that this activity will give a motivator to pharma organizations to create and make new immunizations to battle irresistible maladies. Huge PHARMA-The greater part of Big Pharma organizations are headquartered in the United States, yet a few are situated in western Europe-particularly the United Kingdom, Switzerland, Germany, and France. Most pharma organizations headquartered in the United States are found east of the Mississippi, with the best fixation in New Jersey. Huge Pharma organizations come in two styles: broadened and nondiversified. Differentiated organizations, which incorporate Johnson and Johnson, Abbott Laboratories, and Wyeth, keep up other medicinal services related organizations, for example, shopper wellbeing item divisions and therapeutic gadget organizations, while those that are nondiversified-Eli Lilly, Merck-concentrate exclusively on the advancement and offer of medications. Lately, however, broadened organizations have been stripping their nonpharma worries for the leaner and more productive medication business. Bristol-Myers Squibb, for case, sold Clairol, the main hair-items organization in the United States, to Procter and Gamble in 2001. BIOTECH -In spite of the accomplishment of such biotech mammoths as Amgen and Genentech, a substantial greater part of biotech shops are still sufficiently little for everybody to know others' name. Yet, a developing number is joining the world class gathering of biotech firms that have FDA-affirmed drugs available; somewhere around 2000 and 2003, the FDA endorsed nearly 132 new medications and immunizations and new signs for existing items. Once a biotech organization has achieved the phase at which it has an item coming to market, its employments extend from the essentially science-centered to incorporate promoting, assembling, building, and deals. Socially, organizations have a tendency to have developing agonies as they move from R&D to commercialization, yet their associations have a tendency to stay much leaner and compliment than those in Big Pharma. Despite the fact that there are 1,466 biotech firms in the United States (318 of them traded on an open market), with exactly 200,000 aggregate representatives, the biotech business is altogether littler than the pharma business. Still, this is a dynamic segment. Somewhere around 1992 and 2002, income for the indus - Daily MedNews

Ice Fishing Can Invite Serious Injuries

SATURDAY, Feb. 16, 2017 -- Ice fishing may seem like a relaxing pastime, but it can result in broken bones, concussions and other injuries, according to surgeons from the Mayo Clinic. "Ice fishing has become more popular in the last few years, and,... Posted: Sat 25th of February, 2017

Prison Time Can Be Deadly … to Health

FRIDAY, Feb. 24, 2017 -- Prison time can exact a deadly toll on health, new research suggests. Being behind bars puts people at greater risk for both developing certain types of cancer and dying from their disease, Canadian researchers found. "We... Posted: Fri 24th of February, 2017

The Brain Can Produce Its Own Sugar: Report

FRIDAY, Feb. 24, 2017 -- Scientists are reporting that the brain naturally produces fructose, a type of sugar associated with obesity and type 2 diabetes. The Yale University researchers said follow-up studies will investigate how fructose affects... Posted: Fri 24th of February, 2017

Do You Need an Antibiotic?

FRIDAY, Feb. 24, 2017 -- Hoping to lessen their misery, most people would like to know whether the respiratory illness they've got could be helped by an antibiotic. The key to finding out may lie in your nose. Or, more specifically, the mucus in... Posted: Fri 24th of February, 2017

Live Healthy, Live Longer

FRIDAY, Feb. 24, 2017 -- Want to live a longer, healthier life? Try five simple lifestyle recommendations, a public health expert says. "Stay up to date on immunizations, screening exams for specific types of cancer [e.g., colorectal cancer... Posted: Fri 24th of February, 2017

More Booze Won't Beat Back That Hangover

FRIDAY, Feb. 24, 2017 -- Contrary to what you might want to believe, a hair of the dog isn't the best remedy after a night of heavy drinking, a substance abuse expert warns. "There's no scientific evidence that having an alcoholic drink will cure a... Posted: Fri 24th of February, 2017

Can Depression Up Odds for Arthritis Linked to Psoriasis?

FRIDAY, Feb. 24, 2017 -- Depression in people with the chronic inflammatory skin disease psoriasis increases the risk of getting the joint condition known as psoriatic arthritis by about 37 percent, new research indicates. The finding raises... Posted: Fri 24th of February, 2017

'Superbug' Infections Striking More U.S. Kids

FRIDAY, Feb. 24, 2017 -- A type of antibiotic-resistant bacterial infection has increased 700 percent in American children since 2007, a new investigation reveals. These infections are caused by Enterobacteriaceae bacteria -- normal bacteria that... Posted: Fri 24th of February, 2017

Drug OD Deaths Have Nearly Tripled Since 1999: CDC

FRIDAY, Feb. 24, 2017 -- Drug overdose deaths have nearly tripled in the United States since 1999, with whites and middle-aged Americans bearing much of the brunt, a new government report shows. More than 16 out of every 100,000 Americans died of a... Posted: Fri 24th of February, 2017

Want to Win an Oscar? Study Shows How to Grab the Gold

FRIDAY, Feb. 24, 2017 -- "And the Oscar goes to" . . . an American appearing in a film based on American culture. With the 89th Academy Awards set for Sunday, a new study finds that this type of "U.S.-centric" focus is a key factor boosting the... Posted: Fri 24th of February, 2017

Study Finds Stroke Care Faster for Men Than Women

FRIDAY, Feb. 24, 2017 -- Male stroke patients are more than twice as likely as female patients to receive clot-busting stroke treatment within 30 minutes of hospital arrival, a new study reports. This means men who suffer a stroke are less likely... Posted: Fri 24th of February, 2017

Don't Sweat It: Gender Doesn't Dictate Perspiration Rate

FRIDAY, Feb. 24, 2017 -- Differences in how much men and women sweat have little to do with gender, according to a new study. Instead, sweating is linked to body size, researchers found. This might help explain why larger people -- typically men --... Posted: Fri 24th of February, 2017

Health Highlights: Feb. 24, 2017

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Over 400,000 Toy Frogs Recalled for Injury Hazard Moose Toys says it's recalling hundreds of thousands of Little Live Pets Lil Frog toys, and... Posted: Fri 24th of February, 2017

Health Tip: Babysitter Safety

-- Before letting a babysitter stay with your child, make sure the sitter knows the answers to a few basic safety questions. The University of Michigan Health System suggests discussing: The sitter's knowledge of CPR and first aid. The need to... Posted: Fri 24th of February, 2017

Health Tip: Identifying Signs of the Common Cold

-- Feeling under the weather? It's important to know whether you the common cold or something more serious. The U.S. Centers for Disease Control and Prevention says common-cold symptoms may include: Sore throat. Cough. Sneezing and runny... Posted: Fri 24th of February, 2017

Many Opioid Addicts in Treatment Take Narcotics on the Side

THURSDAY, Feb. 23, 2017 -- Opioid addicts who undergo "medication-assisted treatment" are often using other narcotics before long, a new study cautions. Doctors frequently give addicts buprenorphine, a low-dose opioid, to minimize withdrawal... Posted: Thu 23rd of February, 2017

Could Parkinson's Disease Raise Stroke Risk?

THURSDAY, Feb. 23, 2017 -- A large new analysis suggests there may some type of link between Parkinson's disease and the risk for stroke. However, the study can't prove that one condition causes the other -- or even which direction the link might... Posted: Thu 23rd of February, 2017

Study Links Psychiatric Disorders to Stroke Risk

THURSDAY, Feb. 23, 2017 -- Getting care at a hospital for a psychiatric disorder may be linked to a higher risk of stroke in the following weeks and months, new research suggests. People who sought care at a hospital for serious mental health... Posted: Thu 23rd of February, 2017

NHL Veterans Pledge Their Brains to Research

THURSDAY, Feb. 23, 2017 -- Several former National Hockey League players have joined the growing number of pro athletes who have pledged their brains to research on chronic traumatic encephalopathy (CTE) -- a devastating brain disease that has been... Posted: Thu 23rd of February, 2017

How the Neanderthal in Your Genes Affects Your Health

THURSDAY, Feb. 23, 2017 -- Neanderthals were wiped out about 40,000 years ago, but some of their genes live on in modern humans. And scientists are learning more about what that might mean for our health. Researchers have known for some time that... Posted: Thu 23rd of February, 2017 - Pharma Industry News

Monthly News Roundup - January 2017

Trulance Cleared by FDA for Chronic Idiopathic Constipation (CIC) The U.S. Food and Drug Administration (FDA) has approved Synergy’s Trulance (plecanatide), a uroguanylin analog for the treatment of chronic idiopathic constipation (CIC).... Posted: Tue 31st of January, 2017

FDA Approves Xyrem (sodium oxybate) Oral Solution Generic with a REMS Program

January 18, 2017 -- The FDA has approved the first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease. Cataplexy is a... Posted: Wed 18th of January, 2017

Monthly News Roundup - December 2016

Biogen’s Spinraza Approved for Spinal Muscular Atrophy The U.S. Food and Drug Administration (FDA) has cleared Biogen's Spinraza (nusinersen), the first drug for spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting... Posted: Sat 31st of December, 2016

Monthly News Roundup - November 2016

Novo Nordisk’s Xultophy 100/3.6 FDA-Approved for Type 2 Diabetes This month the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), a once-daily injection of insulin degludec... Posted: Wed 30th of November, 2016

Monthly News Roundup - October 2016

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for... Posted: Mon 31st of October, 2016

Monthly News Roundup - September 2016

Amjevita, a Biosimilar to Humira, Wins FDA Approval Amgen’s Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the U.S. Food and Drug Administration (FDA) and is used for the treatment of seven inflammatory... Posted: Thu 29th of September, 2016

Monthly News Roundup - August 2016

FDA Approves Erelzi: Sandoz’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first... Posted: Thu 1st of September, 2016

FDA Approves First Generic Version of Widely Used Influenza Drug Tamiflu

On August 3, 2016, the U.S. Food and Drug Administration approved the first generic version of Tamiflu (oseltamivir phosphate), a widely used medication for the treatment of the flu (influenza A and B) in patients two weeks of age and older who have... Posted: Fri 5th of August, 2016

Kratom Seized in California by US Marshals Service

August 4, 2016 -- The U.S. Food and Drug Administration announced today that the U.S. Marshals Service seized more than 100 cases of products labeled as containing kratom. The products are distributed by Nature Therapeutics LLC, which does business... Posted: Thu 4th of August, 2016

Monthly News Roundup - July 2016

Injectable Adlyxin FDA-Approved for Type 2 Diabetes The FDA has approved Sanofi’s Adlyxin (lixisenatide), a new once-daily injectable type 2 diabetes medication. Adlyxin is classified as an incretin mimetic/GLP-1 receptor agonist. For... Posted: Sun 31st of July, 2016

FDA Updates Warnings for Fluoroquinolone Antibiotics

July 26, 2016 -- The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and... Posted: Wed 27th of July, 2016

FDA approves first absorbable stent for coronary artery disease

July 5, 2016 -- The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS), which releases the drug everolimus to limit the... Posted: Wed 6th of July, 2016

Monthly News Roundup - June 2016

Epclusa: First Approval For All Major Forms of Chronic Hepatitis C Virus The U.S. Food and Drug Administration (FDA) has given the go-ahead to Epclusa (sofosbuvir and velpatasvir), a nucleotide analog polymerase inhibitor and pan-genotypic NS5A... Posted: Thu 30th of June, 2016

FDA clears first test to detect specific genetic markers for certain antibiotic-resistant bacteria directly from clinical specimens

June 29, 2016 -- The U.S. Food and Drug Administration today cleared for marketing the Xpert Carba-R Assay, an infection control aid that tests patient specimens to detect specific genetic markers associated with bacteria that are resistant to... Posted: Wed 29th of June, 2016

FDA approves implantable device that changes the shape of the cornea to correct near vision

June 29, 2016 -- The U.S. Food and Drug Administration today approved the Raindrop Near Vision Inlay, a device implanted in the cornea (the clear, front surface) of one eye to improve near vision in certain patients with presbyopia. It is the second... Posted: Wed 29th of June, 2016

FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX

June 9, 2016 -- The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 websites that illegally sell potentially dangerous, unapproved... Posted: Thu 9th of June, 2016

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can... Posted: Wed 1st of June, 2016

Monthly News Roundup - May 2016

FDA Approves Zinbryta for Multiple Sclerosis Multiple sclerosis, a chronic, inflammatory, autoimmune disease of the central nervous system, has been reported as the leading cause of disability in young adults 20 to 40 years of age. The US Food... Posted: Wed 1st of June, 2016

FDA takes significant steps to protect Americans from dangers of tobacco through new regulation

May 5, 2016 -- Today, the U.S. Food and Drug Administration finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco and pipe tobacco, among others. This historic rule helps implement the... Posted: Fri 6th of May, 2016

FDA reminds health care professionals not to use drug products intended to be sterile from Medaus

May 5, 2016 -- The U.S. Food and Drug Administration is reminding health care professionals and patients not to use drugs intended to be sterile that were produced by Medaus Inc., due to lack of sterility assurance. The FDA has issued a formal... Posted: Fri 6th of May, 2016 - Clinical Trials

Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone

SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in... Posted: Thu 9th of February, 2017

Armetheon Reaches Agreement With FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 9, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has reached agreement with the U.S. Food and Drug... Posted: Thu 9th of February, 2017

Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

ARDSLEY, N.Y.--(BUSINESS WIRE) February 9, 2017 -- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease... Posted: Thu 9th of February, 2017

MeiraGTx Provides Clinical Trial Updates for Achromatopsia and Leber’s Congenital Amaurosis Ocular Gene Therapy Programs

New York, NY/London, UK, February 8, 2017 /PR NEWSWIRE/ –- MeiraGTx, a New York and London based gene therapy company, announced today the first patient in its clinical study for achromatopsia due to mutations in the CNGB3 gene was treated at the... Posted: Wed 8th of February, 2017

Diffusion Pharmaceuticals’ TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published

CHARLOTTESVILLE, Va., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related... Posted: Wed 8th of February, 2017

BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease

MELVILLE, N.Y., February 8, 2017 – BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has received clearance by the U.S. Food and Drug... Posted: Wed 8th of February, 2017

Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma

NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options,... Posted: Tue 7th of February, 2017

Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings

OXFORD, United Kingdom, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), today... Posted: Wed 1st of February, 2017

AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

NORTH CHICAGO, Ill., Jan. 25, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with... Posted: Wed 25th of January, 2017

ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer

MOUNTAIN VIEW, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers... Posted: Fri 20th of January, 2017

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients

REDWOOD CITY, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing... Posted: Fri 20th of January, 2017

Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer

ROCKVILLE, Md., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced an update on the... Posted: Fri 20th of January, 2017

Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 19, 2017-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 data on edasalonexent in adult subjects. Edasalonexent is a... Posted: Thu 19th of January, 2017

Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies

Osaka, Japan & New York, NY - January 18, 2017 - Takeda Pharmaceutical Company Limited(TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people... Posted: Wed 18th of January, 2017

Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

DUBLIN and BUDAPEST, Hungary, Jan. 17, 2017 /PRNewswire/ -- Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of... Posted: Tue 17th of January, 2017

Tetraphase Pharmaceuticals Doses First Patient In IGNITE3 Phase 3 Clinical Trial of Once-Daily IV Eravacycline in cUTI

WATERTOWN, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company's phase 3 clinical trial evaluating the efficacy and safety of once-daily... Posted: Tue 17th of January, 2017

Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo

MARLBOROUGH, Mass. January 14, 2017 --(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that results of a pivotal Phase 2/3 study (SEP360-202) evaluating novel drug candidate dasotraline in children ages 6 to 12 years with... Posted: Sat 14th of January, 2017

Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial

OSAKA, Japan and FLORHAM PARK, N.J., Jan. 12, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development, met the FDA pre-specified... Posted: Thu 12th of January, 2017

VivaGel BV granted QIDP and Fast Track designation by US FDA

Melbourne, Australia; 12 January 2017: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug... Posted: Thu 12th of January, 2017

Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with Keytruda (pembrolizumab)

WILMINGTON, D.E. & KENILWORTH, N.J. January 9, 2017 – Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program... Posted: Mon 9th of January, 2017